pmpH PCR Assay for Specific LGV Serovar Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing lymphogranuloma venereum (LGV) caused by Chlamydia trachomatis serovars lack specificity and sensitivity, necessitating improved molecular diagnostics to differentiate between LGV and other serovars for appropriate antibiotic treatment.
Innovation Solution
Development of PCR assays targeting unique regions of the pmpH gene in LGV serovars, including a 36 base pair deletion and the 3' end of the gene, for specific and selective detection using primers and probes designed to amplify and hybridize with LGV serovars, enabling real-time detection in a single tube.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If clinical diagnosis and epidemiologic information are used for LGV diagnosis, then the diagnostic process is simple, but the specificity and accuracy are insufficient
Solution Approach 1:
The patent replaces clinical diagnosis and epidemiologic information with molecular nucleic acid amplification testing. The PCR assay uses primers and probes that specifically target the pmpH gene sequence unique to LGV serovars, enabling precise molecular detection that eliminates the need for subjective clinical judgment and provides definitive diagnostic specificity.
2Ease of operation
If generic Chlamydia testing is used, then the test is easy to perform, but it cannot distinguish between LGV and other serovars for appropriate treatment
Solution Approach 1:
The patent applies local quality by designing primers and probes that target a specific local region of the pmpH gene (nucleotides 2600-2900 from the 5' end) that is unique to LGV serovars. This localized targeting allows the test to maintain ease of performance while achieving precise serovar differentiation, as the primers specifically bind to the unique sequence motif present only in LGV strains.
Solution Approach 2:
The patent segments the Chlamydia trachomatis serovars into distinct groups based on their pmpH gene sequences. By identifying and targeting a unique segment (36 nucleotide region) that is present only in LGV serovars and absent in other serovars, the test achieves specific differentiation. This segmentation approach allows the same easy-to-perform PCR assay to distinguish between LGV and non-LGV infections through sequence-specific priming.
3Measurement precision
If a 36 base pair deletion region is targeted for detection, then LGV serovar identification is specific, but the detection requires sophisticated molecular diagnostics
Solution Approach 1:
The patent uses a fluorescent probe as an intermediary that binds to the amplified pmpH gene region containing the 36 bp deletion. The probe carries a fluorescent reporter that emits light only when bound to the specific target sequence, providing a simple visual readout that translates the complex molecular detection into an easily interpretable signal, thereby reducing the perceived complexity while maintaining high specificity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables rapid and accurate identification of LGV serovars in biological samples, ensuring appropriate treatment regimens by distinguishing them from other Chlamydia serovars through fluorescence resonance energy transfer (FRET) or double-stranded DNA binding dyes.
Implementation Method 1
a polymerase chain reaction (PCR) assay
Implementation Method 2
through fluorescence resonance energy transfer (FRET) or double-stranded DNA binding dyes
Implementation Method 3
through fluorescence resonance energy transfer (FRET) or double-stranded DNA binding dyes
Data Source
AI summary
The present disclosure relates, in general, to the methods for the rapid detection of the presence or absence of Lymphogranuloma Venereum (LGV)-causing serovars of Chlamydia trachomatis in a biological or non-biological sample. The methods can include performing an amplification step, a hybridization step, and a detection step. Furthermore, oligonucleotide primers and probes targeting the pmpH gene for the L serovars of Chlamydia trachomatis, along with kits are provided that are designed for the detection of L serovars.